Validity of proton pump inhibitors' prescriptions in a department of internal medicine;Adéquation aux recommandations des prescriptions des inhibiteurs de la pompe à protons dans un service de médecine interne

Revue de Medecine Interne

Volumn 28, Issue 2, 2007, Pages 86-93

  Marie, I ^a   Moutot, A ^b   Tharrasse, A ^b   Hellot, M F ^b   Robaday, S ^a   Herve F ^a   Levesque H ^a  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Family medicine; Indication; Internal medicine; Medical cost; Proton pump inhibitor

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; ESOMEPRAZOLE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IMATINIB; INEXIUM; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PRAVASTATIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; RAMIPRIL; SIMVASTATIN; STEROID; UNCLASSIFIED DRUG; PROTON PUMP;

ADULT; AGED; ARTICLE; BLEEDING; COST BENEFIT ANALYSIS; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG INDICATION; DRUG USE; DUODENUM ULCER; EVALUATION; FRANCE; GASTROESOPHAGEAL REFLUX; GENERAL PRACTITIONER; HELICOBACTER INFECTION; HOSPITAL ADMISSION; HUMAN; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MONEY; PRESCRIPTION; PROSPECTIVE STUDY; QUESTIONNAIRE; STOMACH ULCER; TREATMENT DURATION; ZOLLINGER ELLISON SYNDROME; CLINICAL PRACTICE; DRUG ANTAGONISM; ECONOMICS; FEMALE; GASTROINTESTINAL DISEASE; GENERAL PRACTICE; MALE; MIDDLE AGED; STATISTICS; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; DRUG UTILIZATION REVIEW; FAMILY PRACTICE; FEMALE; FRANCE; GASTROINTESTINAL DISEASES; HUMANS; INTERNAL MEDICINE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES; PROTON PUMPS; QUESTIONNAIRES;

EID: 33846572930     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.09.030     Document Type: Article

References (43)

1. Barradell L.B., Faulds D., and McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 44 (1992) 225-250
2. Howden C.W. Review article : immediate-release proton pump inhibitor therapy - potential advantages. Aliment. Pharmacol. Ther. 22 suppl 3 (2005) 25-30
3. Howden C.W., Henning J.M., Huang B., Lukasik N., and Freston J.W. Management of heartburn in a large, randomized, community-based study: comparison of fur therapeutic strategies. Am. J. Gastroenterol. 96 (2001) 1704-1710
4. Lindberg P., Brandstrom A., Wallmark B., Mattsson H., Rikner L., and Hoffmann K.J. Omeprazole: the first proton pump inhibitor. Med. Res. Rev. 10 (1990) 1-54
5. McTavish D., Buckley M.M., and Heel R.C. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 42 (1991) 138-170
6. Sachs G., Shin J.M., and Howden C.W. Review article: the clinical pharmacology of proton pump inhibitors. Aliment. Pharmacol. Ther. 23 suppl 2 (2006) 2-8
7. Scarpignato C., and Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Aliment. Pharmacol. Ther. 23 suppl 2 (2006) 23-34
8. Caisse nationale d'assurance maladie. Médicaments remboursables : une étude de l'assurance maladie pour comprendre les principales évolutions de l'année 2003. www.amli.fr.
9. Caisse nationale d'Assurance maladie. Médicaments remboursables : une étude de l'assurance maladie pour comprendre les principales évolutions de l'année 2004. www.amli.fr.
10. Caisse nationale d'Assurance maladie. Médicaments remboursables : une étude de l'assurance maladie pour comprendre les principales évolutions de l'année 2005. www.amli.fr.
11. Carvajal A., Arias L.H.M., Vega E., Sanchez J.A.G., Rodriguez I.M., Ortega P.G., et al. Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study. Eur. J. Clin. Pharmacol. 60 (2004) 439-444
12. Heading R.C. Long term management of gastroesophageal reflux disease. Scand. J. Gastroenterol. 30 suppl 213 (1995) 25-29
13. Hungin A.P.S., Rubin G., and O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br. J. Gen. Pract. 49 (1999) 463-464
14. Schindlbeck N.E., Klauser A.G., Berghammer G., Londong W., and Muller-Lissner S.A. Three year follow up of patients with gastrooesophageal reflux disease. Gut 33 (1992) 1016-1019
15. Agence française de sécurité sanitaire des produits de santé (Afssaps) : Recommandations de bonne pratique « les anti-ulcéreux : indications chez l'adulte ». 1999: 1-19. www.agmed,santé.gouv.fr.
16. Conférence de Consensus. Helicobacter pylori-Révisions 1999. Conclusions et recommandations révisées du groupe de travail. Gastroenterol. Clin. Biol. 23 (1999) C95-C104
17. Cerezo Galan A., Diez del Pino A., Simo R.M., Flores J., Freire C., Gallart M.J., et al. Estudio multicentrico prescripcion-indicacion de antiacidos y ulcerosos. Farm. Hosp. 208 (1996) 91-103
18. Naunton M., Peterson G.M., and Bleasel M.D. Overuse of proton pump inhibitors. J. Clin. Pharm. Ther. 25 (2000) 333-340
19. Jones M.I., Greenfield S.M., Jowett S., Bradley C.P., and Seal R. Proton pump inhibitors: a study of GP's prescribing. Fam. Pract. 18 (2001) 333-338
20. Bixquert M. Maintenance therapy in gastro-oesophageal reflux disease. Drugs 65 suppl 1 (2005) 59-66
21. Brun J., Sorngard H., and Swedish multi-centre group in primary health care. High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Fam. Pract. 17 (2000) 401-404
22. Fennerty M.B. Review article: alternative approaches to the long-term management of GERD. Aliment. Pharmacol. Ther. 22 suppl 3 (2005) 39-44
23. Armstrong D. Intravenous proton pump inhibitor therapy: a rationale for use. Rev Gastroenterol Disord 5 suppl 2 (2005) S18-S30
24. Cooper A.L., Langworthy H., and Porter S. Cost-effective prescribing of proton pump inhibitor therapy: an audit in general practice. Int. J. Clin. Pract. 54 (2000) 287-292
25. Clinard F., Bardou M., Sgro C., Lefevre N., Raphael F., Paille F., et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. Eur. J. Clin. Pharmacol. 57 (2001) 737-743
26. Jimenez M.C., Castillo Ferrando J.R., Torello J., Merino N., Maiquez P., Garcia Heras J., et al. Appropriateness of antiulcer drugs prescribing in primary care in Andalucia. Methods Find. Exp. Clin. Pharmacol. 20 (1998) 82
27. Stack W.A., Atherton J.C., Hawkey G.M., Logan R.F.A., and Hawkey C.J. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment. Pharmacol. Ther. 16 (2002) 497-506
28. Liu J.Y., Chen T.J., and Hwang S.J. Concomitant prescription of non-steroidal anti-inflammatory drugs and antiacids in the outpatient setting of a medical center in Taiwan: a prescription database study. Eur. J. Clin. Pharmacol. 57 (2001) 505-508
29. Wolfe F., Anderson J., Burke T.A., Arguelles L.M., and Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J. Rheumatol. 29 (2002) 467-473
30. Bashford J., Norwood J., and Chapman S. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Data Base. BMJ 317 (1998) 452-456
31. Grime J., Pollock K., and Blenkinsopp A. Proton pump inhibitors: perspectives of patients and their GPs. Br. J. Gen. Pract. 51 (2001) 703-711
32. Pollock K., and Grime J. Strategies for reducing the prescribing of proton pump inhibitors (PPIs): patient self-regulation of treatment may be an under-exploited resource. Soc. Sci. Med. 51 (2000) 1827-1839
33. Krol N., Wensing M., Haaijer-Ruskamp F., Muris J.W.M., Numans M.E., Schattenberg G., et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment. Pharmacol. Ther. 19 (2004) 917-922
34. Fossmark R., Johnsen G., Johanessen E., and Waldum H.L. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment. Pharmacol. Ther. 21 (2005) 149-154
35. Hritz I., Herszenyi L., Molnar B., Tulassay A., and Pronai Z. Long-term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression. World J. Gastroenterol. 11 (2005) 4721-4726
36. Laine L., Ahnen D., McClain C., Solcia E., and Walsh J.H. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment. Pharmacol. Ther. 14 (2000) 651-668
37. Waldum H.L., and Brenna E. Personal review: is profound acid inhibition safe?. Aliment. Pharmacol. Ther. 14 (2000) 15-22
38. Wilton L.V., Key C., and Shakir S.A.W. The pharmacovigilance of pantoprazole. The results of postmarketing surveillance on 11 541 patients in England. Drug Saf. 26 (2003) 121-132
39. Haga Y., Nakatsura T., Shibata Y., Sameshima H., Nakamura Y., Tanimura M., et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig. Dis. Sci. 43 (1998) 253-257
40. Jensen R.T. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin. Pharmacol. Toxicol. 98 (2006) 4-19
41. Canani R.B., Cirillo P., Roggero P., Romano C., Malamisura B., Terrin G., et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 117 (2006) e817-e820
42. Dial S., Delaney J.A.C., Barkun A.N., and Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294 (2005) 2989-2995
43. Laheij R.J.F., Sturkenboom M.C.J.M., Hassing R.J., Dieleman J., Stricker B.H.C., and Jansen J.B.M.J. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292 (2004) 1955-1960